Allergen Immunotherapy (AIT) is the only disease modifying treatment option for patient with IgE mediated allergic disorder. Conventional subcutaneous immunotherapy is associated with adverse events during build-up and maintenance phase but cluster allergen immunotherapy with monoclonal anti-IgE antibody (omalizumab) has complementary and synergistic effect. Omalizumab plus AIT can significantly enhance the efficacy, safety, and steroid-sparing effect of AIT by increasing target maintenance dose (TMD) and sustained unresponsiveness (SU) to allergen while decreasing the adverse events and severe systemic reactions. This review aims to highlight that combination of omalizumab plus AIT is superior than AIT alone.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijtb.2024.06.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial: Allergen-specific antibodies: from basic science to clinical application.
Front Allergy
February 2025
Basic Research, InBio, Charlottesville, VA, United States.
Pathogenic and Nonpathogenic Antibody Responses in Allergic Diseases.
Eur J Immunol
March 2025
Institut Pasteur, Université de Paris Cité, Unit of Antibodies in Therapy and Pathology, Paris, France.
Allergen-specific antibodies, particularly of the IgE class, are a hallmark of many allergic diseases. Yet paradoxically, (1) a proportion of healthy individuals possess allergen-specific IgE without clinical signs of allergy; (2) some, but not all, allergic individuals develop a more severe disease over time or fail to respond to allergen-specific immunotherapy; and (3) allergen-specific IgG antibodies can inhibit IgE-mediated responses but they can also induce allergic reactions. In this review, we discuss the occurrence of and transition between nonpathogenic and pathogenic allergen-specific antibody responses in the light of a two-stage model.
View Article and Find Full Text PDFPolymerised mite allergoids with glutaraldehyde reduce proteolytic activity and enhance the stability of allergen mixtures: a proof of concept with grass mixtures.
Front Allergy
February 2025
R&D Department, Fundación Inmunotek, Alcalá de Henares, Spain.
Background: Polysensitized patients require allergen immunotherapy (AIT) targeting multiple allergens. However, combining allergen extracts can lead to instability and reduced efficacy particularly due to the high proteolytic activity of house dust mite (HDM) allergens. While is known that glutaraldehyde cross-linking may reduce enzymatic activity, its ability to stabilize multi-allergen formulations and protect key allergens from degradation remains unexplored.
View Article and Find Full Text PDFBackground: Intradermal allergen testing (IDT) and allergen-specific immunotherapy (ASIT) remain underrated in feline dermatology.
Hypothesis/objectives: The objectives of this retrospective study were to report the results of IDT and the effects of ASIT on the medication needs in a population of 158 cats diagnosed with feline atopic skin syndrome (FASS).
Materials And Methods: FASS was diagnosed after the exclusion of other pruritic conditions.
Allergen Immunotherapy in Autoimmune Terrain: A Case Study.
Indian J Otolaryngol Head Neck Surg
January 2025
Department of Endocrinology, Joshi Clinic, Mumbai, India.
Allergen immunotherapy (AIT), or specific immunotherapy (SIT), is an effective treatment for inducing immune tolerance to specific allergens. It is widely used for allergic rhinitis, conjunctivitis, asthma, and Hymenoptera venom allergies, with recent applications to food allergies and atopic dermatitis. Despite its benefits, the use of SIT in patients with autoimmune diseases is controversial due to concerns about its potential to induce or exacerbate autoimmune conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!